Clarivate Introduces New OFF-X ™ Platform for Preclinical and Clinical Safety Intelligence
Rhea-AI Summary
Clarivate Plc (NYSE:CLVT) has launched the new OFF-X™ platform, an enhanced solution for preclinical and clinical safety intelligence in biopharma. The platform offers a seamless user experience and unique translational insights, delivering important drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence™, OFF-X™ provides a comprehensive resource for safety information, streamlining processes and enhancing efficiency.
Key improvements include an 80% reduction in loading times for targets, drugs, drug combinations, and adverse events, faster search capabilities, clearer visual design, full-screen visualization, and additional analytic tools. The platform empowers users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities, and de-risk assets across all phases of drug R&D and post-marketing.
Positive
- Launch of enhanced OFF-X™ platform for improved safety intelligence
- 80% reduction in loading times for key data
- Integration with Cortellis Drug Discovery Intelligence™ for comprehensive safety information
- Enhanced functionality including faster search and additional analytic tools
Negative
- None.
Insights
Clarivate's launch of the new OFF-X™ platform marks a significant advancement in preclinical and clinical safety intelligence for the biopharma industry. The platform's integration with Cortellis Drug Discovery Intelligence™ creates a powerful, unified resource for comprehensive safety information.
Key technical improvements include:
- An 80% reduction in loading times for critical data points such as targets, drugs, drug combinations and adverse events.
- Enhanced search capabilities for faster data retrieval.
- Improved visual design for better user experience.
- Full-screen visualization options for detailed data analysis.
- Additional analytic tools to derive deeper insights.
These enhancements collectively contribute to a more efficient and user-friendly experience, potentially saving valuable time in drug development processes. The platform's ability to provide translational insights could be particularly valuable in bridging the gap between preclinical and clinical stages, a critical point where many drug candidates fail.
From a technological standpoint, the mention of an 'upgraded technology stack' suggests Clarivate has likely implemented more modern, scalable technologies. This could improve the platform's performance, reliability and ability to handle large datasets - important factors in the data-intensive field of drug safety analysis.
While the platform shows promise, it's important to note that its effectiveness will ultimately depend on the quality and comprehensiveness of the underlying data, as well as the sophistication of its analytical algorithms. The true value of these technological improvements will be realized as users integrate the platform into their workflows and assess its impact on decision-making processes in drug development.
The introduction of Clarivate's enhanced OFF-X™ platform represents a significant development in the realm of drug safety intelligence. This tool has the potential to substantially impact the drug development process, particularly in the critical areas of risk assessment and mitigation.
Key benefits for medical research include:
- Proactive identification of safety risks across all phases of drug R&D and post-marketing.
- Comprehensive monitoring of toxicology and safety signals.
- Enhanced ability to mitigate safety liabilities and de-risk assets.
- Streamlined access to important safety information.
The platform's integration with Cortellis Drug Discovery Intelligence™ is particularly noteworthy. This combination creates a unified resource that could significantly reduce the time researchers spend searching for and compiling safety data from disparate sources.
The 80% reduction in loading times for targets, drugs, drug combinations and adverse events is a substantial improvement. In the fast-paced world of drug development, this speed increase could translate to more efficient decision-making processes and potentially faster progression through development stages.
However, it's important to remember that while such platforms can greatly assist in identifying potential risks, they cannot replace the need for rigorous clinical trials and expert interpretation of data. The true value of OFF-X™ will be determined by its ability to accurately predict and help mitigate real-world safety issues in drug development.
Ultimately, if the platform delivers on its promises, it could contribute to more informed decision-making in drug development, potentially leading to safer drugs reaching patients more quickly and efficiently. This could have far-reaching implications for both the pharmaceutical industry and public health.
Empowering biopharma with enhanced safety insights to anticipate risks and unlock new competitive advantages
The new platform features an upgraded technology stack and enhanced functionality while retaining its core capabilities. These improvements include an
Justin Hubbard, Vice President, Product Management, Life Sciences and Healthcare at Clarivate, said: "The launch of the new OFF-X™ platform underscores our dedication to providing actionable, comprehensive solutions in life sciences and healthcare. OFF-X revolutionizes access to safety information across all drug R&D and post-marketing phases, with speed and customization. By combining our safety intelligence with advanced analytics, we empower clients to accelerate the delivery of safe, effective and commercially successful treatments to patients."
OFF-X empowers users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities and de-risk assets across all phases of drug R&D and post-marketing, bolstering confident development and investment decisions.
Learn more about OFF-X here.
About OFF-X™
OFF-X is the new translational safety intelligence platform that facilitates integrated preclinical toxicity data, clinical and pharmacovigilance adverse event data, visualizations and preclinical safety analytics. Updated daily, the platform incorporates wide-ranging analytics and visualizations, as well as comprehensive range of safety information sources and datasets, including a range of over 15,000 targets and more than 39,000 drugs & biologics, populated with almost 3 million expertly curated safety alerts associated to 14,000 adverse events and toxicity endpoints.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact:
Luna Ivkovic,
External Communications, Life Sciences & Healthcare
newsroom@clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-introduces-new-off-x--platform-for-preclinical-and-clinical-safety-intelligence-302207891.html
SOURCE Clarivate Plc
FAQ
What is the new OFF-X™ platform launched by Clarivate (CLVT)?
How does the new OFF-X™ platform improve efficiency for Clarivate (CLVT) users?
What are the key benefits of Clarivate's (CLVT) new OFF-X™ platform for drug development?
How does Clarivate's (CLVT) OFF-X™ platform integrate with other solutions?
